Study: Majority of CBD Businesses Are Operating in FDA ‘Gray Area’
More than 90 percent of CBD companies are operating in the “FDA gray area,” meaning that their products don’t have approvals from the Food and Drug Administration (FDA) and have a fair chance of being rejected by the federal agency in the future. Among the over 2,000 cannabis-related businesses and investment deals tracked by market…